Researchers at the Stanford Alzheimer’s Disease Research Center (ADRC) will shortly begin human clinical trials of the approach and technology they hope will spell the end of neurodegenerative diseases, such as Alzheimer’s. The approach combines 3D printing with nanotechnology, gene therapy, and CRISPR technology to produce and deliver functional neurons to the damaged areas of the brain.

The research, led by Dr Megan Stables, was hugely successful in rats and mice, and human trials are scheduled to start next month. “This could transform the field of neuroscience and we are excited to kick off the next phase of trials,” said Dr Stables.

“We 3D print custom-designed scaffolds that mimic the structure of the brain, which are then seeded with engineered cells to replace damaged neurons,” explains Dr Stables. “Gene therapy and CRISPR technology are then used to modify the cells before implantation to ensure they have the correct genetic profile and express the appropriate genes to promote the formation of functional neuronal networks. Nanotechnology delivers the neurons, drugs, and other therapeutic agents to the injury site to promote healing and prevent further damage.”

While the potential benefits of this technology for the treatment of Alzheimer’s and dementia are clear, there are also broader implications for medicine and beyond. The ability to 3D print custom-engineered cells and tissues could revolutionize the way we approach regenerative medicine and the treatment of a wide range of diseases, injuries, and disabilities.

As we continue to advance the science of 3D and 4D printing and regenerative medicine, we can expect to see more breakthroughs like this one, with the potential to change the face of healthcare and improve the lives of millions of people around the world.